Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 839

1.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, López PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J.

Invest New Drugs. 2019 May 7. doi: 10.1007/s10637-019-00783-7. [Epub ahead of print]

PMID:
31065954
2.

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.

de Man FM, Veerman GDM, Oomen-de Hoop E, Deenen MJ, Meulendijks D, Mandigers CMPW, Soesan M, Schellens JHM, van Meerten E, van Gelder T, Mathijssen RHJ.

Ther Adv Med Oncol. 2019 Apr 15;11:1758835919838964. doi: 10.1177/1758835919838964. eCollection 2019.

3.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.

Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J.

J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20.

PMID:
30892987
4.

Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.

Rolfo C, de Vos-Geelen J, Isambert N, Molife LR, Schellens JHM, De Grève J, Dirix L, Grundtvig-Sørensen P, Jerusalem G, Leunen K, Mau-Sørensen M, Plummer R, Learoyd M, Bannister W, Fielding A, Ravaud A.

Clin Pharmacokinet. 2019 Mar 16. doi: 10.1007/s40262-019-00754-4. [Epub ahead of print]

PMID:
30877569
5.

Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.

de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, Huitema ADR, Beijnen JH.

Cancer Med. 2019 Apr;8(4):1406-1415. doi: 10.1002/cam4.2003. Epub 2019 Feb 22.

6.

Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.

Roosendaal J, Wang K, Rosing H, Lucas L, Gebretensae A, Oganesian A, Schellens JHM, Beijnen JH, Lin ZJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:132-141. doi: 10.1016/j.jchromb.2019.01.011. Epub 2019 Jan 22.

PMID:
30754019
7.

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, Otten HM, Bergman AM, Schellens JHM, Beijnen JH, Huitema ADR.

Drugs Aging. 2019 Apr;36(4):379-385. doi: 10.1007/s40266-019-00643-2.

PMID:
30734241
8.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply.

Henricks LM, Lunenburg CATC, Cats A, Mathijssen RHJ, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2019 Feb;20(2):e67. doi: 10.1016/S1470-2045(19)30010-5. No abstract available.

PMID:
30712800
9.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Crombag MBS, de Vries Schultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR.

Pharm Res. 2019 Jan 7;36(2):33. doi: 10.1007/s11095-018-2563-6.

PMID:
30617624
10.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM.

Ann Oncol. 2019 Feb 1;30(2):219-235. doi: 10.1093/annonc/mdy551.

PMID:
30608567
11.

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.

de Weger VA, de Jonge M, Langenberg MHG, Schellens JHM, Lolkema M, Varga A, Demers B, Thomas K, Hsu K, Tuffal G, Goodstal S, Macé S, Deutsch E.

Br J Cancer. 2019 Feb;120(3):286-293. doi: 10.1038/s41416-018-0355-8. Epub 2018 Dec 26.

PMID:
30585255
12.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.

PMID:
30544060
13.

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.

Verheijen RB, Thijssen B, Atrafi F, Schellens JHM, Rosing H, de Vries N, Beijnen JH, Mathijssen RHJ, Steeghs N, Huitema ADR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 1;1104:234-239. doi: 10.1016/j.jchromb.2018.11.030. Epub 2018 Nov 30.

PMID:
30530116
14.

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants.

Lunenburg CATC, Henricks LM, van Kuilenburg ABP, Mathijssen RHJ, Schellens JHM, Gelderblom H, Guchelaar HJ, Swen JJ.

Genes (Basel). 2018 Nov 28;9(12). pii: E585. doi: 10.3390/genes9120585.

15.

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.

Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM.

Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.

PMID:
30485432
16.

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Sparidans RW, Wang Y, Schinkel AH, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Dec 1;1102-1103:167-172. doi: 10.1016/j.jchromb.2018.10.023. Epub 2018 Oct 30.

17.

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid.

Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM.

J Pharm Biomed Anal. 2019 Feb 5;164:128-134. doi: 10.1016/j.jpba.2018.10.025. Epub 2018 Oct 17.

PMID:
30368118
18.
19.

Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.

Lunenburg CATC, Henricks LM, Dreussi E, Peters FP, Fiocco M, Meulendijks D, Toffoli G, Guchelaar HJ, Swen JJ, Cecchin E, Schellens JHM, Gelderblom H.

Eur J Cancer. 2018 Nov;104:210-218. doi: 10.1016/j.ejca.2018.07.138. Epub 2018 Oct 23.

PMID:
30361102
20.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.

PMID:
30348537
21.

Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells.

Jacobs BAW, Pluim D, van der Laan P, Tzani A, Beijnen JH, Schellens JHM.

Nucleosides Nucleotides Nucleic Acids. 2018;37(8):436-454. doi: 10.1080/15257770.2018.1498270. Epub 2018 Oct 4.

PMID:
30285552
22.

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):168-175. doi: 10.1038/s41391-018-0096-z. Epub 2018 Oct 2.

PMID:
30279580
23.

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.

Sparidans RW, Li W, Schinkel AH, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Nov 30;161:136-143. doi: 10.1016/j.jpba.2018.08.038. Epub 2018 Aug 19.

PMID:
30149189
24.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?

Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Br J Clin Pharmacol. 2018 Dec;84(12):2770-2778. doi: 10.1111/bcp.13725. Epub 2018 Sep 26.

PMID:
30068020
25.

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N, Rosing H, Beijnen JH, Huitema ADR, Guchelaar HJ, Cats A, Schellens JHM.

Br J Clin Pharmacol. 2018 Dec;84(12):2761-2769. doi: 10.1111/bcp.13719. Epub 2018 Sep 25.

26.

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

van Andel L, Rosing H, Schellens JH, Beijnen JH.

Mar Drugs. 2018 Jul 23;16(7). pii: E246. doi: 10.3390/md16070246. Review.

27.

Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position.

Ciccolini J, Del Re M, Danesi R, Milano G, Schellens JHM, Raymond E.

Ann Oncol. 2018 Sep 1;29(9):1893-1894. doi: 10.1093/annonc/mdy258. No abstract available.

PMID:
30032203
28.

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.

van Nuland M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, Rosing H, Schellens JHM, Beijnen JH, Hövels AM.

Breast Cancer Res Treat. 2018 Nov;172(1):143-150. doi: 10.1007/s10549-018-4886-8. Epub 2018 Jul 13.

29.

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin.

van Andel L, Rosing H, Tibben MM, Lucas L, Lubomirov R, Avilés P, Francesch A, Fudio S, Gebretensae A, Hillebrand MJX, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Sep;82(3):441-455. doi: 10.1007/s00280-018-3637-1. Epub 2018 Jul 4.

PMID:
29974200
30.

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Kip AE, Wasunna M, Alves F, Schellens JHM, Beijnen JH, Musa AM, Khalil EAG, Dorlo TPC.

Front Cell Infect Microbiol. 2018 Jun 1;8:181. doi: 10.3389/fcimb.2018.00181. eCollection 2018.

31.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.

van Andel L, Rosing H, Lubomirov R, Avilés P, Fudio S, Tibben MM, Nan-Offeringa L, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Sep 5;158:160-165. doi: 10.1016/j.jpba.2018.05.053. Epub 2018 Jun 1.

PMID:
29883879
32.

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.

van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, Nayak TK, Stokkel MPM, Mulder ER, Hoekstra OS, Vugts DJ, Van Dongen GAMS, Verheul HM, Evers S, Tessier JJL, Saro J, Schellens JHM, Menke-van der Houven van Oordt CW.

Oncotarget. 2018 May 15;9(37):24737-24749. doi: 10.18632/oncotarget.25343. eCollection 2018 May 15.

33.

Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology.

Groenland SL, van Nuland M, Verheijen RB, Schellens JHM, Beijnen JH, Huitema ADR, Steeghs N.

Clin Pharmacokinet. 2019 Mar;58(3):299-308. doi: 10.1007/s40262-018-0683-0. Review.

PMID:
29862467
34.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF.

Cancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30.

PMID:
29848605
35.

Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.

Rood JJM, Dormans PJA, van Haren MJ, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:14-21. doi: 10.1016/j.jchromb.2018.05.011. Epub 2018 May 11.

36.

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.

Von Hoff DD, Rasco DW, Heath EI, Munster PN, Schellens JHM, Isambert N, Tourneau CL, O'Neil B, Mathijssen RHJ, Lopez-Martin JA, Edenfield WJ, Martin M, LoRusso PM, Bray GL, DiMartino J, Nguyen A, Liu K, Laille E, Bendell JC.

Clin Cancer Res. 2018 Sep 1;24(17):4072-4080. doi: 10.1158/1078-0432.CCR-17-3716. Epub 2018 May 15.

PMID:
29764853
37.

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Kip AE, Castro MDM, Gomez MA, Cossio A, Schellens JHM, Beijnen JH, Saravia NG, Dorlo TPC.

J Antimicrob Chemother. 2018 Aug 1;73(8):2104-2111. doi: 10.1093/jac/dky143.

PMID:
29757380
38.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J, Los-de Vries GT, Horlings H, Nuijen B, Beijnen JH, Schellens JHM, Bernards R.

Cell. 2018 May 31;173(6):1413-1425.e14. doi: 10.1016/j.cell.2018.04.012. Epub 2018 May 10.

39.

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.

de Vries Schultink AHM, Doornbos RP, Bakker ABH, Bol K, Throsby M, Geuijen C, Maussang D, Schellens JHM, Beijnen JH, Huitema ADR.

Invest New Drugs. 2018 Dec;36(6):1006-1015. doi: 10.1007/s10637-018-0593-x. Epub 2018 May 5.

40.

Solubility and bioavailability improvement of pazopanib hydrochloride.

Herbrink M, Groenland SL, Huitema ADR, Schellens JHM, Beijnen JH, Steeghs N, Nuijen B.

Int J Pharm. 2018 Jun 10;544(1):181-190. doi: 10.1016/j.ijpharm.2018.04.037. Epub 2018 Apr 19.

PMID:
29680279
41.

Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.

Spatari C, Li W, Schinkel AH, Ragno G, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:204-208. doi: 10.1016/j.jchromb.2018.03.014. Epub 2018 Mar 9.

42.

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.

Dean E, Banerji U, Schellens JHM, Krebs MG, Jimenez B, van Brummelen E, Bailey C, Casson E, Cripps D, Cullberg M, Evans S, Foxley A, Lindemann J, Rugman P, Taylor N, Turner G, Yates J, Lawrence P.

Cancer Chemother Pharmacol. 2018 May;81(5):873-883. doi: 10.1007/s00280-018-3558-z. Epub 2018 Mar 14.

43.

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Derissen EJB, Huitema ADR, Rosing H, Schellens JHM, Beijnen JH.

Br J Clin Pharmacol. 2018 Jun;84(6):1279-1289. doi: 10.1111/bcp.13557. Epub 2018 Apr 16.

44.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E.

Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5.

45.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.

Jacobs BAW, Snoeren N, Samim M, Rosing H, de Vries N, Deenen MJ, Beijnen JH, Schellens JHM, Koopman M, van Hillegersberg R.

Eur J Clin Pharmacol. 2018 Jun;74(6):737-744. doi: 10.1007/s00228-018-2426-4. Epub 2018 Feb 11.

PMID:
29430582
46.

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

de Vries Schultink AHM, Boekhout AH, Gietema JA, Burylo AM, Dorlo TPC, van Hasselt JGC, Schellens JHM, Huitema ADR.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):431-442. doi: 10.1007/s10928-018-9579-8. Epub 2018 Feb 10.

47.

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J.

J Clin Oncol. 2018 May 1;36(13):1291-1299. doi: 10.1200/JCO.2017.72.7107. Epub 2018 Feb 5. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):361. J Clin Oncol. 2019 Feb 1;37(4):361.

48.

Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations.

van Berlo-van de Laar IRF, Brummelhuis WJ, Imholz ALT, Schellens JH, Huitema ADR, Jansman FGA.

J Clin Pharm Ther. 2018 Aug;43(4):574-577. doi: 10.1111/jcpt.12661. Epub 2018 Jan 5.

PMID:
29315736
49.

Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.

van Nuland M, Hillebrand MJX, Rosing H, Burgers JA, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Mar 20;151:25-31. doi: 10.1016/j.jpba.2017.12.048. Epub 2017 Dec 26.

PMID:
29294409
50.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N, Beijnen JH, Steeghs N, Huitema ADR.

Ther Drug Monit. 2018 Apr;40(2):230-236. doi: 10.1097/FTD.0000000000000479.

PMID:
29256969

Supplemental Content

Loading ...
Support Center